Mustang Bio (Mustang Bio) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Mustang Bio's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Mustang Bio's average Total Assets over the quarter that ended in Mar. 2024 was $16.17 Mil. Therefore, Mustang Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

Mustang Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Mustang Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mustang Bio Gross-Profit-to-Asset % Chart

Mustang Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

Mustang Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Mustang Bio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Mustang Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mustang Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Mustang Bio's Gross-Profit-to-Asset % falls into.

Mustang Bio Gross-Profit-to-Asset % Calculation

Mustang Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (92.422	+	17.742)	/ 2 )
	=	0	/	55.082
	=	0.00 %

Mustang Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (17.742	+	14.592)	/ 2 )
	=	0	/	16.167
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Mustang Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Mustang Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mustang Bio (Mustang Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

377 Plantation Street, Worcester, MA, USA, 01605

Website

https://www.mustangbio.com

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.

Executives

Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman	director, officer: President and CEO	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach	officer: SVP, Fin. & Corp. Controller	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill	director	24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky	director
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020